argenx SE (NASDAQ: ARGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $521.00 price target on the stock.
argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $451.00 price target on the stock.
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Here's Why argenx SE (ARGX) Pulled Back 23% in Q4 [Yahoo! Finance]
argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $451.00 price target on the stock.